Mounjaro and underactive thyroid: can you take it safely?

The critical distinction: hypothyroidism versus thyroid cancer history

The first thing to settle is what kind of thyroid situation we are actually talking about. An underactive thyroid (hypothyroidism) is a common condition in which the thyroid gland does not produce enough hormone, typically managed with daily levothyroxine. That is a very different picture from a history of medullary thyroid carcinoma (MTC) or a genetic condition called Multiple Endocrine Neoplasia type 2 (MEN2), and the two categories carry different clinical weight when it comes to GLP-1 medicines.

Tirzepatide's prescribing information lists a personal or family history of MTC, or a diagnosis of MEN2, as reasons not to use the medicine. This comes from animal studies in which high doses of GLP-1 receptor agonists caused thyroid C-cell tumours; it has not been replicated in human data at therapeutic doses, but the precautionary exclusion stands. Read more about the thyroid cancer question if that history is relevant to you.

Straightforward hypothyroidism with no cancer history is a separate matter, and you can read a full overview of Mounjaro and thyroid conditions to understand where the medicine stands on each of them. What the Mounjaro SmPC does flag is that your prescriber should have a complete picture of your medical history. Telling your clinician you take levothyroxine is not a hurdle, it is essential information that shapes safe prescribing.

How Mounjaro may interact with levothyroxine

Levothyroxine is one of the more demanding medicines to take correctly. It needs to be taken on an empty stomach, usually first thing in the morning, with a gap before food or other tablets. Absorption varies enough that even small changes in routine can shift thyroid function tests meaningfully over time.

Tirzepatide slows gastric emptying, that is part of how it reduces appetite and extends feelings of fullness. This effect is most noticeable early in treatment and after dose increases. The concern is not dramatic, but it is real: slower gastric motility could alter how consistently levothyroxine is absorbed, particularly if the two medicines happen to be taken close together.

The practical guidance from clinicians in this area is consistent: keep your levothyroxine routine as stable as possible, take it at the same time relative to meals and other medicines as you always have, and flag any new or returning hypothyroid symptoms to your GP. If you start Mounjaro and notice a return of fatigue, feeling cold, or unexpected weight changes, those symptoms deserve a thyroid function check rather than an assumption that treatment is not working. Our page on how Mounjaro can affect thyroid function goes into the mechanism in more detail.

The NHS England guidance on weight management injections advises telling your healthcare team about all medicines you take before starting, for exactly this kind of reason.

What is still uncertain, and who decides

Clinical research specifically on people with treated hypothyroidism taking tirzepatide for weight management is limited. The SURMOUNT clinical programme enrolled thousands of adults with obesity, including people with multiple weight-related conditions, but the trials were not designed to report separately on thyroid subgroups. That means the interaction picture described above is based on pharmacology and clinical experience rather than a dedicated head-to-head study.

What that means for you is straightforward: this is not a decision a webpage should make. A prescriber who can see your full thyroid history, your current levothyroxine dose, your most recent thyroid function results, and your overall health picture is the right person to make this call. Our prescribers carry out that clinical review personally for every consultation, your answers are read by a qualified clinician, not processed by an automated system. If you are unsure whether your thyroid history makes Mounjaro unsuitable, the consultation is where that gets resolved, not before it.

You might find it useful to have a recent thyroid function result to hand when you consult; if one is not available, your GP can arrange one. Explore the broader picture of thyroid conditions and tirzepatide for a fuller clinical overview, or visit our FAQs for general questions about the consultation process.

Starting Mounjaro when you have an underactive thyroid: the practical picture

If your hypothyroidism is well controlled on levothyroxine and you have no history of MTC or MEN2, there is no automatic barrier to being assessed for Mounjaro. The conversation with your prescriber will focus on your thyroid history, your current medication, and how well your condition is managed. Poorly controlled hypothyroidism is itself a cause of weight gain and fatigue, symptoms that overlap with how some people feel in the first weeks of tirzepatide treatment. Stabilising thyroid function before starting weight-loss treatment tends to give a cleaner baseline.

One thing worth knowing: the starter dose of tirzepatide is deliberately low. The 2.5mg pen your treatment would begin with is not a therapeutic dose in the weight-loss sense; it exists to help your body adjust and minimise early side effects, and our guidance on Mounjaro and age eligibility explains why the medicine is currently approved only for adults. If gastrointestinal effects do occur in those first weeks, keep taking your levothyroxine as normal and let your prescriber know, there is no reason to pause it.

If you are considering treatment, start a free consultation with our prescribers. If you want to read more before deciding, our weight-loss treatment overview sets out the options clearly. And if you have questions about the team behind the service, meet our clinical lead.